• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·SGP
Share

SpyGlass Pharma, Inc. Common Stock Stocks

$ 18.81Last Updated 25.06.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 653.62M

$ 18.81
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

06.02.2026 14:58

SpyGlass Pharma IPO: developer of eye disease therapy device goes public

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

No company description

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of SGP is 47 and suggests 148% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

27.06.2026 03:48

OpenAI restricted access to the new version of ChatGPT at the request of the Trump administration

27.06.2026 03:12

Moderna shares hit a two-year high after a 13% surge. It's all about a new treatment

27.06.2026 01:53

The U.S. launched strikes against Iran in response to an attack on a commercial vessel in the Strait of Hormuz

27.06.2026 01:07

The Nasdaq fell 4% following the worst week of the year for semiconductor stocks

27.06.2026 00:12

Bitcoin is at a two-year low. When will it be safe to start buying it again?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026